LH stock forecast: what analysts expect
Wall Street analysts covering Labcorp Holdings Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $337.75 — +4.4% versus the last price of $323.48. Targets reflect analyst opinion, not a guarantee.
LH historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in LH.
LH annual returns by year
Congress trading in LH
8 members of Congress have disclosed trading LH — 10 purchases and 5 sales worth an estimated $287,000. Most recent disclosure: Feb 4, 2026.
See who in Congress traded LH →Insider activity in LH
LH's own executives and directors have made 0 open-market purchases ($0) and 7 sales ($2.5M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 11, 2026.
| Aug 11, 2026 | Schechter Adam H | President & CEO | Sell | $1.5M |
| Aug 4, 2026 | Summy Amy B. | EVP, Chief Marketing Officer | Sell | $283,428 |
| Aug 3, 2026 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell | $25,356 |
| Aug 3, 2026 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell | $413,751 |
| Jul 2, 2026 | Kyle Kathryn W | EVP, Chief Legal Officer | Sell | $26,329 |
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
LH Key Statistics
LH in plain English
- P/E ratio (26.7) — how many dollars you pay for each $1 of LH's yearly profit. That's a fairly normal range.
- ROE (11.73%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (6.99%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (0.89%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
LH stock: frequently asked questions
What is Labcorp Holdings Inc.'s stock price today?
Labcorp Holdings Inc. (LH) last traded at $323.48 on the NYSE. Over the past 52 weeks the stock has traded between $244.52 and $323.97.
Is LH stock a buy or a sell?
Wall Street analysts' consensus rating on LH is "Buy", with an average 12-month price target of $337.75 — about +4.4% versus the current price of $323.48. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in LH 10 years ago be worth today?
A $1,000 investment in Labcorp Holdings Inc. made 10 years ago would be worth about $2,894 today (dividends reinvested) — a total return of 189%, or 11.2% per year.
Does LH pay a dividend?
Yes. Labcorp Holdings Inc. currently pays a dividend yielding about 0.89% per year at today's share price.
What is LH's P/E ratio?
LH trades at a trailing price-to-earnings ratio of 26.7, and 16.4 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade LH stock?
Yes — 8 members of Congress have disclosed trades in LH under the STOCK Act, totaling 10 purchases and 5 sales worth an estimated $287,000.
What is Labcorp Holdings Inc.'s ticker symbol?
Labcorp Holdings Inc. trades under the ticker symbol LH on the NYSE.
Compare LH with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.